secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001099800-23-000042
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards plans tax-free spin-off of Critical Care, issues 2024 sales guidance $6.3-6.6B
--------------------------------------------------------------------------------

- Edwards plans tax-free spin-off of Critical Care at end of 2024; Katie Szyman to be CEO of new company.
- 2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80.
- 2024 TAVR sales $4.0-4.3B (8-10% growth); TMTT sales $280-320M.
- Board authorized $1B additional share repurchase authorization.
- Clinical milestones: PROGRESS enrollment complete early 2024, EARLY TAVR data at TCT 2024, EVOQUE US approval mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000042/0001099800-23-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980023000042/ew-20231207.htm
  HTML page:      https://secwatch.observer/filing/0001099800-23-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer